Felsenstein, Kevin M.

Dynamics of β-Amyloid Reductions in Brain, Cerebrospinal Fluid, and Plasma of β-Amyloid Precursor Protein Transgenic Mice Treated with a γ-Secretase Inhibitor

Barten, D. M., Guss, V. L., Corsa, J. A., Loo, A., Hansel, S. B., Zheng, M., Munoz, B., Srinivasan, K., Wang, B., Robertson, B. J., et al. (2005) · The Journal of Pharmacology and Experimental Therapeutics

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 159

Comment on “ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models.”

Price, A. R., Xu, G., Siemienski, Z. B., Smithson, L. A., Borchelt, D. R., Golde, T. E., & Felsenstein, K. M. (2013) · Science

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 138

Altered cleavage and secretion of a recombinant β–APP bearing the Swedish familial Alzheimer's disease mutation

Felsenstein, K. M., Hunihan, L. W., & Roberts, S. B. (1994) · Nature Genetics

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 90

Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice

Rogers, K., Felsenstein, K. M., Hrdlicka, L., Tu, Z., Albayya, F., Lee, W., Hopp, S., Miller, M.-J., Spaulding, D., Yang, Z., et al. (2012) · Molecular Neurodegeneration

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 75

Emerging β-Amyloid Therapies for the Treatment of Alzheimers Disease

Conway, K., Baxter, E., Felsenstein, K., & Reitz, A. (2003) · Current Pharmaceutical Design

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 40